{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:04:06Z","timestamp":1784347446689,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007195","name":"University of Naples Federico II","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106830","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T23:08:07Z","timestamp":1762038487000},"page":"106830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-EBV antibody reduction during ocrelizumab treatment is not associated with multiple sclerosis outcomes"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9042-9866","authenticated-orcid":false,"given":"Antonio","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Corsaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Delle Cave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Nicolella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Affinito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Selvaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Portella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Castaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2613-3090","authenticated-orcid":false,"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2025.106830_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200250","article-title":"Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis","volume":"11","author":"Abbadessa","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2025.106830_bib0011","doi-asserted-by":"crossref","first-page":"869","DOI":"10.17219\/acem\/172240","article-title":"Unleashing the power of anti-CD20 immunotherapy: mitigating multiple sclerosis risk in Epstein\u2013Barr virus latent infections","volume":"33","author":"Alrashoudi","year":"2023","journal-title":"Adv. Clin. Experim. Med"},{"key":"10.1016\/j.msard.2025.106830_bib0006","article-title":"Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"9","author":"Bjornevik","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106830_bib0017","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00415-022-11350-1","article-title":"Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study","volume":"270","author":"Capasso","year":"2023","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106830_bib0012","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics."},{"issue":"9","key":"10.1016\/j.msard.2025.106830_bib0016","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/ene.13669","article-title":"No evidence of disease activity\u2019 \u2013 is it an appropriate surrogate in multiple sclerosis?","volume":"25","author":"Hegen","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106830_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr Virus and Systemic Autoimmune Diseases","volume":"11","author":"Houen","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2025.106830_bib0015","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1093\/brain\/awv258","article-title":"Defining reliable disability outcomes in multiple sclerosis","volume":"138","author":"Kalincik","year":"2015","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.msard.2025.106830_bib0021","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ni835","article-title":"A functional and structural basis for TCR cross-reactivity in multiple sclerosis","volume":"3","author":"Lang","year":"2002","journal-title":"Nat. Immunol."},{"issue":"14","key":"10.1016\/j.msard.2025.106830_bib0014","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1177\/13524585231205973","article-title":"Worsening MS\u2014A reappraisal of how we characterize the MS disease course","volume":"29","author":"Lublin","year":"2023","journal-title":"Multiple Sclerosis J"},{"issue":"6","key":"10.1016\/j.msard.2025.106830_bib0001","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106830_bib0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106830_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104497","article-title":"The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment","volume":"70","author":"Pham","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106830_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105037","article-title":"Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy","volume":"79","author":"R\u00f8d","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106830_bib0020","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/brain\/awae244","article-title":"Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation","volume":"148","author":"Schneider-Hohendorf","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106830_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106695","article-title":"Evaluating the role of anti-EBV antibodies as biomarkers for the evolution of multiple sclerosis: a longitudinal study","volume":"103","author":"Semy","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2025.106830_bib0008","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J. Exp. Med."},{"issue":"24","key":"10.1016\/j.msard.2025.106830_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00980-19","article-title":"Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: clue for a Virus-Driven Immunopathological Mechanism","volume":"93","author":"Serafini","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.msard.2025.106830_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578314","article-title":"EBV infected cells in the multiple sclerosis brain express PD-L1: how the virus and its niche may escape immune surveillance","volume":"389","author":"Serafini","year":"2024","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2025.106830_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/35095584","article-title":"Epstein-Barr virus: exploiting the immune system","volume":"1","author":"Thorley-Lawson","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106830_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104094","article-title":"Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study","volume":"67","author":"Zivadinov","year":"2022","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:39:01Z","timestamp":1784345941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"alternative-id":["S2211034825005723"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106830","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-EBV antibody reduction during ocrelizumab treatment is not associated with multiple sclerosis outcomes","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106830"}}